Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors.

To discover safe and effective topical skin-lightening agents, we have evaluated alkyl esters of the natural product gentisic acid (GA), which is related to our lead compound methyl gentisate (MG), and four putative tyrosinase inhibitors, utilizing mammalian melanocyte cell cultures and cell-free extracts. Desirable characteristics include the ability to inhibit melanogenesis in cells (IC50 < 100 microg/mL) without cytotoxicity, preferably due to tyrosinase inhibition. Of the six esters synthesized, the smaller esters (e.g. methyl and ethyl) were more effective enzyme inhibitors (IC50 approximately 11 and 20 microg/mL, respectively). For comparison, hydroquinone (HQ), a commercial skin "bleaching" agent, was a less effective enzyme inhibitor (IC50 approximately 72 microg/mL), and was highly cytotoxic to melanocytes in vitro at concentrations substantially lower than the IC50 for enzymatic inhibition. Kojic acid was a potent inhibitor of the mammalian enzyme (IC50 approximately 6 microg/mL), but did not reduce pigmentation in cells. Both arbutin and magnesium ascorbyl phosphate were ineffective in the cell-free and cell-based assays. MG at 100 microg/mL exhibited a minimal inhibitory effect on DHICA oxidase (TRP 1) and no effect on DOPAchrome tautomerase (TRP-2), suggesting that MG inhibits melanogenesis primarily via tyrosinase inhibition. MG and GA were non-mutagenic at the hprt locus in V79 Chinese hamster cells, whereas HQ was highly mutagenic and cytotoxic. The properties of MG in vitro, including (1) pigmentation inhibition in melanocytes, (2) tyrosinase inhibition and selectivity, (3) reduced cytotoxicity relative to HQ, and (4) lack of mutagenic potential in mammalian cells, establish MG as a superior candidate skin-lightening agent.

[1]  M. Fukuda,et al.  Arbutin: mechanism of its depigmenting action in human melanocyte culture. , 1996, The Journal of pharmacology and experimental therapeutics.

[2]  G. Imokawa,et al.  Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. , 1994, The EMBO journal.

[3]  I. Jackson,et al.  A second tyrosinase‐related protein, TRP‐2, is a melanogenic enzyme termed DOPAchrome tautomerase. , 1992, The EMBO journal.

[4]  C. Smith,et al.  Selective cytotoxicity of hydroquinone for melanocyte-derived cells is mediated by tyrosinase activity but independent of melanin content. , 1988, Pigment cell research.

[5]  J. Pawelek,et al.  Dopachrome conversion: a possible control point in melanin biosynthesis. , 1980, The Journal of investigative dermatology.

[6]  H. Glatt,et al.  Fjord- and bay-region diol-epoxides investigated for stability, SOS induction in Escherichia coli, and mutagenicity in Salmonella typhimurium and mammalian cells. , 1991, Cancer research.

[7]  R. Spritz,et al.  Mutational analysis of copper binding by human tyrosinase. , 1997, The Journal of investigative dermatology.

[8]  I. Whimster Pigment-Cell Biology , 1968, Nature.

[9]  J. Bergman,et al.  Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. , 1993, Journal of Pharmacology and Experimental Therapeutics.

[10]  H. Glatt Endogenous mutagens derived from amino acids. , 1990, Mutation research.

[11]  P. Smith,et al.  Direct analysis of salicylic acid, salicyl acyl glucuronide, salicyluric acid and gentisic acid in human plasma and urine by high-performance liquid chromatography. , 1996, Journal of chromatography. B, Biomedical applications.

[12]  R. Spritz,et al.  Genetic disorders of pigmentation. , 1994, Advances in human genetics.

[13]  K. Kilgore,et al.  Development of an in vitro primary screen for skin depigmentation and antimelanoma agents. , 1994, Skin pharmacology : the official journal of the Skin Pharmacology Society.

[14]  H. Glatt,et al.  Activation of N-acetoxy- and N-hydroxy-2-acetylaminofluorene to mutagenic and cytotoxic metabolites by V79 Chinese hamster cells. , 1985, Mutation research.

[15]  K. Yasunobu Mode of Action of Tyrosinase , 1959 .

[16]  V. Hearing Mammalian monophenol monooxygenase (tyrosinase): purification, properties, and reactions catalyzed. , 1987, Methods in enzymology.

[17]  F. García-Carmona,et al.  Kojic Acid, a Cosmetic Skin Whitening Agent, is a Slow‐binding Inhibitor of Catecholase Activity of Tyrosinase , 1994, The Journal of pharmacy and pharmacology.

[18]  H. Glatt,et al.  Multiple activation pathways of benzene leading to products with varying genotoxic characteristics. , 1989, Environmental health perspectives.

[19]  D. Bucks,et al.  Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. , 1996, Journal of the American Academy of Dermatology.

[20]  T. Dooley Topical skin depigmentation agents: current products and discovery of novel inhibitors of melanogenesis , 1997 .

[21]  D. Bennett,et al.  A line of non‐tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth , 1987, International journal of cancer.

[22]  K. Lerch Protein and active-site structure of tyrosinase. , 1988, Progress in clinical and biological research.

[23]  K. Halprin,et al.  A sensitive fluorometric assay method for mammalian tyrosinase. , 1967, Biochemical and biophysical research communications.

[24]  B. Du Alcaptonuria and ochronotic arthritis. , 1991 .